These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2016-004259-59 Multi-center, single-arm, open-label study in patients with Insomnia Disorder to validate the Insomnia Daytime Symptoms and Impacts Questionnaire™ (IDSIQ™) 2017-06-12 due-trials
Reported results 2017-000494-36 A Phase 2a, multi-center, single-blind, within-subject, placebo-controlled study to assess the pharmacodynamics of ACT-709478 in subjects with photosensitive epilepsy 2018-04-25 due-trials
Reported results 2017-003332-36 A multi-center, double-blind, randomized, placebo-controlled study to assess the pharmacodynamics, pharmacokinetics, tolerability, and safety of a single subcutaneous injection of ACT-246475 in adults... 2018-09-18 due-trials
Listed as ongoing, but also has a completion date and reported results 2017-003369-85 A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease Studio mul... 2021-09-02 bad-data
Listed as ongoing, but also has a completion date and reported results 2017-004393-33 Multi-center, blinded, randomized, parallel-group, Phase 3 study with aprocitentan in subjects with Resistant Hypertension (RHT) 2022-04-25 bad-data
Reported results 2017-004642-20 Multi-center, double-blind, randomized, placebo-controlled, parallel-group, polysomnography study to assess the efficacy and safety of ACT-541468 in adult and elderly subjects with insomnia disorder 2020-02-25 due-trials
Reported results 2017-004643-20 Multi-center, double-blind, randomized, placebo-controlled, parallel-group, polysomnography study to assess the efficacy and safety of ACT-541468 in adult and elderly subjects with insomnia disorder 2020-05-14 due-trials
Reported results 2017-004644-38 Multi-center, double-blind, parallel-group, randomized, placebo-controlled, three doses, 40-week extension to studies ID-078A301 and ID-078A302 to assess the long term safety and tolerability of ACT-5... 2021-02-22 due-trials
Listed as ongoing, but also has a completion date and reported results 2018-000241-39 A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, Phase 3 study to assess the efficacy and safety of clazosentan in preventing clinical deterioration due to de... 2022-11-18 bad-data
Reported results 2018-000765-36 A multi-center, open-label, randomized, study to assess the onset of platelet aggregation inhibition after a single subcutaneous injection of ACT-246475 in adults with acute myocardial infarction 2018-11-10 due-trials
Reported results 2018-000851-42 A randomized, double-blind, placebo-controlled, 12-week treatment study to evaluate the effect of ACT-774312 in subjects with bilateral nasal polyposis 2020-12-01 due-trials
Listed as ongoing, but also has a completion date and reported results 2018-001808-11 A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic... 2022-08-22 bad-data
Ongoing 2018-002210-12 A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease not-yet-due
Reported results Terminated 2018-003819-22 Multi-center, blinded, randomized study with aprocitentan in subjects with uncontrolled blood pressure and chronic kidney disease stage 3 or 4. 2019-12-18 due-trials
Ongoing 2020-000983-41 Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and ... not-yet-due
Ongoing 2021-003867-87 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography, Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-dose Oral Administratio... not-yet-due
Other 2022-002814-17 A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe sys... not-yet-due
Other 2022-002815-47 A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe sys... not-yet-due